Author

A. T. Fabro

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Immunology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

F. P. Veras· 3 shared G. F. Gomes· 3 shared S. S. Batah· 3 shared A. C. Puhl· 2 shared F. Cunha· 2 shared J. C. Alves-Filho· 2 shared S. Damasceno· 2 shared S. Ekins· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

F. P. Veras

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Deep learning for histopathological subtyping and grading of lung adenocarcinoma

K. Lami, N. Ota, S. Yamaoka, A. Bychkov, K. Matsumoto, W. Uegami, R. Attanoos, S. Berezowska, L. Brcic, A. Cavazza, J. English, A. T. Fabro, K. Ishida, Y. Kashima, Y. Kitamura, , J. Fukuoka

This study develops CNNs to subtype and grade lung adenocarcinoma, achieving high accuracy and outperforming most pathologists in grading prediction.

bioRxiv · Nov 2, 2022 · PreprintPathology

Targeting Neutrophils Extracellular Traps (NETs) reduces multiple organ injury in a COVID-19 mouse model

F. P. Veras, G. F. Gomes, B. M. Silva, C. Almeida, C. M. Silva, A. H. Schneider, E. S. Corneo, C. S. Bonilha, S. S. Batah, R. P. Martins, E. Arruda, A. T. Fabro, J. C. A. Alves-Filho, T. M. Cunha, F. Q. Cunha

This study shows that DNase I treatment reduces NETs and organ injury in a COVID-19 mouse model.

bioRxiv · Apr 27, 2022Pharmacology & Toxicology

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice

A. C. Puhl, G. F. Gomes, S. Damasceno, E. J. Fritch, J. A. Levi, N. J. Johnson, F. Scholle, L. Premkumar, B. L. Hurst, F. LeeMontiel, F. P. Veras, S. S. Batah, A. T. Fabro, N. J. Moorman, B. Yount, , S. Ekins

This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.

bioRxiv · Dec 16, 2021 · PreprintImmunology

Pyronaridine Protects Against SARS-CoV-2 in Mouse

A. C. Puhl, G. F. Gomes, S. Damasceno, A. S. de Godoy, G. D. Noske, A. M. Nakamura, V. O. Gawrijuk, R. S. Fernandes, N. Monakhova, O. Riabova, T. R. Lane, V. Makarov, F. P. Veras, S. S. Batah, A. T. Fabro, , S. Ekins

Pyronaridine reduces SARS-CoV-2 viral load and lung pathology in mice, with in vitro inhibition of viral PLpro and host kinase CAMK1.

bioRxiv · Sep 30, 2021 · PreprintPharmacology & Toxicology